Skip to main content
Open Access Publications from the University of California

Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques.

  • Author(s): Escolano, Amelia
  • Gristick, Harry B
  • Abernathy, Morgan E
  • Merkenschlager, Julia
  • Gautam, Rajeev
  • Oliveira, Thiago Y
  • Pai, Joy
  • West, Anthony P
  • Barnes, Christopher O
  • Cohen, Alexander A
  • Wang, Haoqing
  • Golijanin, Jovana
  • Yost, Daniel
  • Keeffe, Jennifer R
  • Wang, Zijun
  • Zhao, Peng
  • Yao, Kai-Hui
  • Bauer, Jens
  • Nogueira, Lilian
  • Gao, Han
  • Voll, Alisa V
  • Montefiori, David C
  • Seaman, Michael S
  • Gazumyan, Anna
  • Silva, Murillo
  • McGuire, Andrew T
  • Stamatatos, Leonidas
  • Irvine, Darrell J
  • Wells, Lance
  • Martin, Malcolm A
  • Bjorkman, Pamela J
  • Nussenzweig, Michel C
  • et al.

Broadly neutralizing monoclonal antibodies protect against infection with HIV-1 in animal models, suggesting that a vaccine that elicits these antibodies would be protective in humans. However, it has not yet been possible to induce adequate serological responses by vaccination. Here, to activate B cells that express precursors of broadly neutralizing antibodies within polyclonal repertoires, we developed an immunogen, RC1, that facilitates the recognition of the variable loop 3 (V3)-glycan patch on the envelope protein of HIV-1. RC1 conceals non-conserved immunodominant regions by the addition of glycans and/or multimerization on virus-like particles. Immunization of mice, rabbits and rhesus macaques with RC1 elicited serological responses that targeted the V3-glycan patch. Antibody cloning and cryo-electron microscopy structures of antibody-envelope complexes confirmed that immunization with RC1 expands clones of B cells that carry the anti-V3-glycan patch antibodies, which resemble precursors of human broadly neutralizing antibodies. Thus, RC1 may be a suitable priming immunogen for sequential vaccination strategies in the context of polyclonal repertoires.

Main Content
Current View